文献速递水电解质与酸碱遗传性与小管间质肾病血液净化与透析

透析治疗肾功能正常的家族性肿瘤性钙化症一例

Dialysis as a Treatment Option for a Patient With Normal Kidney Function and Familial Tumoral Calcinosis Due to a Compound Heterozygous FGF23 Mutation.
PubMed 文献 · Am J Kidney Dis · 2018-03-14

本文报道一例28岁男性家族性肿瘤性钙化症患者,表现为多发疼痛性硬块,生化示高磷血症、血钙正常、肾功能正常、FGF23不可测,基因分析发现FGF23复合杂合突变。因缺乏其他治疗选择且面临严重血管并发症,在肾功能正常情况下启动每日血液透析,成功控制高磷血症并缩小转移性肿瘤病灶。

要点

  • 肾功能正常的高磷血症伴异位钙化需警惕肿瘤性钙化症。
  • FGF23基因复合杂合突变可导致FGF23不可测及高磷血症。
  • 每日血液透析可有效控制肾功能正常患者的高磷血症并缩小钙化灶。

核心结论

  • 在FGF23复合杂合突变所致肿瘤性钙化症且肾功能正常的患者中,每日血液透析可有效控制高磷血症并缩小转移性肿瘤病灶。

研究设计与样本

  • 个案报道:1例28岁男性,有右左臀部、右锁骨区、膝和左肘疼痛性硬块病史。

主要发现

  • 血磷9.0 mg/dL,血钙4.8 mg/dL,肾功能正常,磷排泄分数3%。
  • 甲状旁腺激素抑制至15 pg/mL,25-羟基维生素D 26 ng/mL,1,25-二羟基维生素D 92 pg/mL。
  • 血清完整FGF23不可测。
  • 基因分析示FGF23复合杂合突变c.201G>C(p.Gln67His)和c.466C>T(p.Gln156*)。
  • 每日血液透析成功控制高磷血症并缩小转移性肿瘤病灶。

临床怎么用

  • 对肾功能正常但高磷血症伴异位钙化者,应考虑肿瘤性钙化症并检测FGF23及基因。
  • 在缺乏其他治疗选择且面临严重血管并发症时,可考虑每日血液透析作为控制高磷血症和钙化灶的治疗选项。

局限性

  • 单个病例报道,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary tumoral calcinosis is a rare autosomal recessive disorder characterized by ectopic calcified tumoral masses. Mutations in 3 genes (GALNT3, FGF23, and KL) have been linked to this human disorder. We describe a case of a 28-year-old man with a history of painful firm masses over his right and left gluteal region, right clavicle region, knees, and left elbow. Biochemical analysis disclosed hyperphosphatemia (phosphate, 9.0 mg/dL) and normocalcemia (calcium, 4.8 mg/dL), with normal kidney function and fractional excretion of phosphate of 3%. Parathyroid hormone was suppressed (15 pg/mL), associated with a low-normal 25-hydroxyvitamin D (26 ng/mL) concentration but high 1,25-dihydroxyvitamin D concentration (92 pg/mL). Serum intact FGF-23 (fibroblast growth factor 23) was undetectable. Genetic analysis revealed tumoral calcinosis due to a compound heterozygous mutation in FGF23, c.201G>C (p.Gln67His) and c.466C>T (p.Gln156*). Due to lack of other treatment options and because the patient was facing severe vascular complications, we initiated a daily hemodialysis program even in the setting of normal kidney function. This unusual therapeutic option successful controlled hyperphosphatemia and reduced metastatic tumoral lesions. This is a report of a new mutation in FGF23 in which dialysis was an effective treatment option for tumoral calcinosis with normal kidney function.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Goldenstein PT, Neves PD, Balbo BE, et al. Dialysis as a Treatment Option for a Patient With Normal Kidney Function and Familial Tumoral Calcinosis Due to a Compound Heterozygous FGF23 Mutation. Am J Kidney Dis. 2018. PMID: 29548779. doi:10.1053/j.ajkd.2017.12.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。